Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 07/29 10:00:16 pm
125.23 USD   +0.62%
04:57a BOSTON SCIENTIF : After stumbling big, Boston Scientific has regaine..
07/30 JOHNSON & JOHNS : Operation Family Caregiver Expands to Washington S..
07/28 Weak China sales drag down Smith & Nephew profits
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Recalls Nearly 54,000 Packages Of Imodium Antidiarrhea Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
05/17/2012 | 07:41pm CEST
   By Peter Loftus 

Johnson & Johnson (JNJ) has recalled nearly 54,000 packages of Imodium Multi-Symptom Relief antidiarrhea pills due to a potential packaging defect.

J&J's McNeil consumer-health division said Thursday an internal review revealed the potential for a limited number of blister-packaging units--which contain the pills--to have dents with a small pinhole or tear.

J&J said the voluntary recall was being conducted at the wholesale level only, and not from consumers or store shelves. J&J said there were no safety concerns or adverse events associated with the recall.

The company said consumers may continue to use the product if there is no hole or tear in the blister unit. An Imodium caplet taken from a damaged blister unit, however, may not provide the full benefit of the product as intended. J&J advised patients not to take the product if the blister unit is torn or open.

J&J said it has made improvements to the packaging line to try to prevent the issue from happening again.

J&J has manufactured more than 2.75 million packages of Imodium Multi-Symptom Relief Caplets over the past five months, and except for the one lot being recalled, the product remains on store shelves, said spokeswoman Barbara Montresor.

J&J's McNeil unit has issued a series of recalls for popular over-the-counter medicines like Tylenol over the past two and a half years for various quality lapses. The recalls have cost the company hundreds of millions of dollars in lost sales and costs to fix the manufacturing problems.

More information about the recall can be found at the Imodium product website: http://www.imodium.com/page.jhtml?id=imodium/include/news.inc.

J&J shares rose 0.2% to $63.81 in recent trading.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
04:57a BOSTON SCIENTIFIC : After stumbling big, Boston Scientific has regained its stri..
07/30 JOHNSON & JOHNSON : Operation Family Caregiver Expands to Washington State and N..
07/29 JOHNSON & JOHNSON : Operation Family Caregiver Expands to Washington State and N..
07/28 Johnson & Johnson Reports 2016 Second-Quarter Results
07/28 JOHNSON & JOHNSON : RefleXion Medical Extends Series B Financing to $52 Million ..
07/28 Weak China sales drag down Smith & Nephew profits
07/27DJExperimental Alzheimer's Drug Fails in Trial
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J deal
07/26 JOHNSON & JOHNSON : Janssen Announces Clinical Collaboration with Bristol-Myers ..
07/26 JOHNSON & JOHNSON : Daratumumab (DARZALEX®) Granted Breakthrough Therapy Designa..
More news
Sector news : Pharmaceuticals - NEC
07/30DJMERCK : Earnings Watch -- WSJ
07/30 BAYER : says will halt future U.S. sales of insecticide
07/29DJTech Stocks Up On Google Earnings - Tech Roundup
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/30 LANCASTER COLONY : A Dividend King With 53 Years Of Dividend Increases (Part 13 ..
07/30 RESURGENCE OF LANNETT : A Growing Opportunity
07/30 VistaGen Is An Interesting Opportunity, Following Allergan's Anti-Depressant ..
07/28 Guest Charles Gooch, Jr. (Part 2) - Dividend Health Checkup Podcast - Episode..
07/27 Johnson & Johnson Delivers Strong Results
Financials ($)
Sales 2016 72 078 M
EBIT 2016 21 811 M
Net income 2016 16 515 M
Finance 2016 13 414 M
Yield 2016 2,51%
P/E ratio 2016 21,28
P/E ratio 2017 18,83
EV / Sales 2016 4,59x
EV / Sales 2017 4,29x
Capitalization 344 463 M
More Financials
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 0,93%
Consensus details
EPS Revisions
More Estimates Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.91%344 463
PFIZER INC.14.28%223 732
ROCHE HOLDING LTD.-10.46%218 231
NOVARTIS AG-5.30%215 109
MERCK & CO., INC.11.06%162 372
More Results